362 related articles for article (PubMed ID: 11974864)
21. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer.
Bi H; Yin L; Fang W; Song S; Wu S; Shen J
Lab Med; 2023 Jul; 54(4):372-379. PubMed ID: 36282321
[TBL] [Abstract][Full Text] [Related]
22. [Study on the value of tumor markers ProGRP, CYFRA21-1, NSE and CEA in the differential diagnosis of pleural effusion].
Liu Y; Yu L; Lin J
Zhongguo Fei Ai Za Zhi; 2006 Jun; 9(3):273-6. PubMed ID: 21172161
[TBL] [Abstract][Full Text] [Related]
23. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
24. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
25. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
[TBL] [Abstract][Full Text] [Related]
28. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors.
Molina R; Filella X; Augé JM; Fuentes R; Bover I; Rifa J; Moreno V; Canals E; Viñolas N; Marquez A; Barreiro E; Borras J; Viladiu P
Tumour Biol; 2003; 24(4):209-18. PubMed ID: 14654716
[TBL] [Abstract][Full Text] [Related]
29. [Lung cancer].
Komagata H; Yoneda S
Gan To Kagaku Ryoho; 2004 Oct; 31(10):1609-13. PubMed ID: 15508459
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
Lai RS; Chen CC; Lee PC; Lu JY
Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
[TBL] [Abstract][Full Text] [Related]
32. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
33. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z
Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663
[TBL] [Abstract][Full Text] [Related]
34. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
Plebani M; Basso D; Navaglia F; De Paoli M; Tommasini A; Cipriani A
Br J Cancer; 1995 Jul; 72(1):170-3. PubMed ID: 7541234
[TBL] [Abstract][Full Text] [Related]
35. Utility of tumour markers in the diagnosis of neoplastic pleural effusion.
San Jose ME; Alvarez D; Valdes L; Sarandeses A; Valle JM; Penela P
Clin Chim Acta; 1997 Sep; 265(2):193-205. PubMed ID: 9385461
[TBL] [Abstract][Full Text] [Related]
36. [Diagnostic value of the tumor markers TPA-M, CYPFRA 21-1 and CEA in pleural effusion. Prospective comparison of thoracoscopic investigations in patients with pleural effusion].
Riedel U; Schönfeld N; Savaser A; Serk M; Loddenkemper R
Pneumologie; 1999 Oct; 53(10):471-6. PubMed ID: 10596548
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of serum tumor markers in patients with lung cancer.
Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
[TBL] [Abstract][Full Text] [Related]
38. Tumor markers in pleural effusions.
Topolcan O; Holubec L; Polivkova V; Svobodova S; Pesek M; Treska V; Safranek J; Hajek T; Bartunek L; Rousarova M; Finek J
Anticancer Res; 2007; 27(4A):1921-4. PubMed ID: 17649796
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
40. Differential diagnosis of tuberculous and malignant pleural effusions: comparison of the Th1/Th2 cytokine panel, tumor marker panel and chemistry panel.
Zhang J; Chen Y; He G; Jiang X; Chen P; Ouyang J
Scand J Clin Lab Invest; 2020 Jul; 80(4):265-270. PubMed ID: 32108543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
